Walter Weller, president and COO of MedPro, said: “The Insulin Guard meets a significant need in the home healthcare market for a truly passive safety self-injector that can diminish the risk of accidental needle sticks and related transfer of blood borne pathogens.”
“A substantial portion of the diabetic public, both in the United States and worldwide, administer insulin through routine injections in the home. Sharps that remain exposed after use are responsible for accidental needle sticks in the home each year. Additional needle stick injuries occur during the disposal and transfer of sharps waste from the home environment. The ‘fully passive’ safety system on the Insulin Guard automatically encloses the contaminated end of the needle immediately after use, thus protecting the patient, the patient’s family, and caregivers. Since the contaminated sharp remains completely covered after use, everyone involved in waste disposal is also protected. We are also investigating the possible use of the Insulin Guard in the hospital setting, which would significantly expand the potential market opportunity.”
Visual Connections is transferring this technology to MedPro for a 5% royalty on adjusted net sales after commercialization. MedPro intends to market the Insulin Guard to both current and potential global medical device partners who would in turn brand and sell the Insulin Guard to their worldwide customer base.